Tirzepatide

Tirzepatide (brand names Mounjaro, Zepbound) is a dual GLP-1 and GIP receptor agonist—it targets two metabolic pathways instead of one. The dual action produces more weight loss than single-pathway GLP-1 medications like semaglutide. FDA-approved for type 2 diabetes and weight management.

Semaglutide targets one receptor pathway. Tirzepatide targets two—producing greater weight loss in head-to-head studies (average ~20% body weight loss on tirzepatide vs ~15% on semaglutide at 12 months). Tirzepatide costs more. Side effect profile is similar. We'll discuss which fits you.

Most patients lose 15–22% of body weight over 12 months at therapeutic dose. Some patients lose more, some less—depends on baseline weight, lifestyle integration, and individual response. First month is dose-finding (slower loss); peak monthly loss typically at months 3–6.

Weekly self-administered subcutaneous injection using a small needle. We teach you the technique at your first visit. Injections take seconds, with rotating sites on the thigh, abdomen, or upper arm.

Starting at $375/month for compounded tirzepatide including medication, supplies, and provider visits. Pricing increases with dose escalation. Initial labs: $150–$250. Higher cost than semaglutide reflects medication pricing differences.

Similar profile to semaglutide. Common: nausea (especially during dose increases), constipation or diarrhea, occasional vomiting, fatigue in first weeks. Rare: pancreatitis, gallbladder issues with rapid weight loss. Most side effects resolve as your body adjusts.

Yes. We can prescribe with appropriate BMI (typically 27+ with comorbidities, or 30+ without) after evaluation. Our physician director reviews each case. Medical decision, not cosmetic.

Depends on goals, budget, and how your body responds. Tirzepatide typically produces more weight loss per month but costs more. Semaglutide is well-studied and more affordable. Some patients start with semaglutide and switch to tirzepatide if response is inadequate. We'll discuss at consultation.

Most patients who stop see partial weight regain—the medication addresses ongoing appetite regulation. Long-term low-dose maintenance is common. Some patients can taper after building strong lifestyle habits. We discuss long-term planning from the start.

Sometimes yes for diabetes (Mounjaro), often no for weight management (Zepbound). Coverage depends on your plan and diagnosis. We provide documentation you can submit but don't bill insurance directly.

Same contraindications as semaglutide: personal/family history of medullary thyroid cancer, MEN syndrome, pancreatitis history, severe gastroparesis, pregnancy. We screen thoroughly before prescribing.

Comprehensive metabolic panel including lipids, A1c, kidney and liver function, thyroid panel, lipase. We monitor at 3 and 6 months after starting, then annually.

We provide nutrition guidance focused on adequate protein (preserving muscle), hydration, fiber, and avoiding nutrient deficiencies. Hyper-restrictive diets aren't necessary—tirzepatide naturally reduces appetite, often more dramatically than semaglutide.

Yes—resistance training (weights) is especially important to preserve muscle during rapid weight loss. Cardio supports health but isn't required for weight loss. Building muscle while losing fat produces better long-term outcomes.

Book a wellness consultation. We'll discuss goals, review medical history and labs, evaluate appropriateness, and design a treatment plan with honest pricing. If tirzepatide isn't right for you, we'll tell you. Call (806) 701-5840 or book online.